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A randomized, double-blind, multicenter study of indinavir, zidovudine, and lamivudine
was conducted in 320 adults with human immunodeficiency virus type 1 (HIV-1) infection,
<50 CD4 cells/mm3, and extensive prior zidovudine therapy. Patients received indinavir, 800
mg every 8 h; zidovudine, 200 mg every 8 h, and lamivudine, 150 mg twice daily; or all 3
drugs for 24 weeks. In an intention-to-treat analysis, proportions of patients with HIV-1 RNA
!500 and !50 copies/mL, respectively, at week 24 were 56% and 45% in the indinavir-zido-
vudine-lamivudine group, 3% and 2% in the indinavir group, and 0% in the zidovudine-
lamivudine group. Observed mean CD4 cell increases were 95, 78, and 6 cells/mm3 in the
three-, one-, and two-drug arms, respectively. Regimens were generally well tolerated. Patients
with advanced HIV-1 infection benefit from triple therapy with indinavir, zidovudine, and
lamivudine, although the proportion with optimal response appeared to be lower in patients
with low CD4 cell counts.
Combination therapy with indinavir, zidovudine, and lami-
vudine slows disease progression in patients with human im-
munodeficiency virus (HIV) type 1 infection who have <200
CD4 cells/mm3 [1]. In addition, therapy with this triple com-
bination results in prolonged suppression of HIV replication,
as measured by serum or plasma viral RNA levels, especially
among subjects with 150 CD4 cells/mm3 [2, 3]. Although some
studies have included patients with <50 CD4 cells/mm3, few
studies have focused on this population with advanced HIV-1
infection, where chances for durable antiretroviral responses
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are less and chances for toxicity are great [4]. In this study, we
compared the antiretroviral efficacy and safety of the combi-
nation of indinavir, zidovudine, and lamivudine with dual ther-
apy with zidovudine plus lamivudine and with monotherapy
with indinavir in zidovudine-experienced patients with <50
CD4 cells/mm3.
Methods
Study design and patient selection. The study was a double-
blind, randomized, 6-month study in HIV-1–seropositive patients
who had an average of 2 pretreatment CD4 cell counts of <50
cells/mm3. Patients, >18 years of age, were required to have had
>6 months of prior zidovudine treatment and no prior treatment
with protease inhibitors or lamivudine. No restrictions existed on
prior use of other approved antiretroviral drugs.
Eligible patients were required to discontinue their antiretroviral
therapy 2 weeks before study entry and were randomly assigned
to 1 of 3 treatment regimens: indinavir, 800 mg every 8 h (Crixivan;
Merck, West Point, PA); the combination of indinavir, 800 mg every
8 h, zidovudine, 200 mg every 8 h (Retrovir, Glaxo Wellcome,
Research Triangle Park, NC), and lamivudine, 150 mg twice daily
(Epivir; Glaxo Wellcome); or the combination of zidovudine, 200
mg every 8 h, and lamivudine, 150 mg twice daily. The regimens
included appropriate matching placebos. Patients were randomized
within study site by use of a permuted block design. In all, 320
patients enrolled in the study at 21 sites between August 1995 and
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April 1996. After 24 weeks, all patients were eligible to continue
taking open-label indinavir, 800 mg every 8 h, and other approved
antiretroviral agents.
Here we present complete data pertaining to the first 24 weeks
of the study, including available viral RNA and CD4 cell data at
week 84 from patients randomized to the triple therapy arm. The
primary measures of efficacy were the changes in serum HIV RNA
levels and CD4 cell counts. In addition, we analyzed the time to
progression to an AIDS-defining illness or death.
Patient monitoring. After randomization, subjects were seen
at weeks 0, 2, 4, and every 4 weeks thereafter through week 24,
when study medication was discontinued, and 2 weeks after the
last dose of the study drug. An attempt was made to continue to
follow persons who discontinued the study drug. At each visit,
patients had physical examinations, and blood and urine samples
were collected for safety testing, measurement of HIV RNA levels,
and CD4 cell counts. All laboratory tests were performed at a
central laboratory with the exception of one site, whose location
prohibited the use of a central laboratory for safety testing and
CD4 cell counts. Women of childbearing potential had serum preg-
nancy tests done at each visit; women who became pregnant were
required to discontinue participation in the study. Information col-
lected at each visit included study and concomitant therapy taken
since the last visit, adverse events, and clinical events.
Clinical events were defined as AIDS-defining illnesses that met
specific diagnostic criteria defined in the protocol and death due
to any cause. The clinical events and the supporting diagnostic
information were reviewed and confirmed by a single investigator
selected by Merck as a study representative. The investigator was
blinded to allocation number, site, and treatment group at the time
of the review.
CD4 cell count and serum HIV RNA testing. CD4 cells were
measured by a central laboratory using 3-color flow cytometry for
all but one international site. Values of!10 cells/mm3 were reported
as !10 cells/mm3. For the 3 patients at one international site, testing
was done at a local laboratory using 2-color flow cytometry. CD4
cell count results were made available to the patients and
investigators.
Sera for HIV-1 RNA levels were processed, stored at 2707C,
and assayed at a later date by a quantitative reverse transcriptase
polymerase-chain reaction (PCR) assay (Amplicor HIV-1 Monitor
assay; Roche Diagnostics Systems, Branchburg, NJ) at a central
laboratory. The lower level of quantification for this assay was 500
RNA copies/mL. A value of “negative” was reported if no copies
were detectable. If virus was detectable but the number of copies
was !500 copies/mL, a value of !500 copies/mL was reported. A
more sensitive investigational version of the PCR assay was per-
formed on samples from week 24 and later visits for which the
result was negative or !500 copies/mL. The investigational assay
had a consistent limit of detection of ∼50 RNA copies/mL. HIV
RNA results were not made available to the patients or investi-
gators during the first 24 weeks of the study.
Statistical methods. The primary measures of antiretroviral
activity were the magnitude and duration of changes in serum HIV
RNA and CD4 cell counts over 24 weeks, as summarized by an
area-under-the-curve measurement that incorporated the baseline
value and length of follow-up (AUCMB) [5, 6]. All patients with
measurements at baseline and at least one on treatment were in-
cluded in the analyses. HIV RNA values reported as !500 copies/
mL were set equal to 500 copies/mL, and values reported as “neg-
ative” were set equal to 250 copies/mL, half of the limit of quan-
tification. The HIV RNA values underwent a log10 transformation
before analysis. CD4 cell counts reported as !10 cells/mm3 were
set equal to 5 cells/mm3. The AUCMBs, which estimated the av-
erage change from baseline, were compared among the treatment
groups with an analysis of variance model that included treatment
group and investigative site. Mean changes and SEs, adjusted for
site, and the nominal P values for the pairwise comparisons of the
treatments are reported. Observed mean changes from baseline plus
the 95% confidence interval (CI) at each week are displayed.
Per the protocol, the average change in CD4 cell count was the
primary end point and the average change in HIV RNA level was
secondary. During the time the study was conducted, changes in
HIV RNA became at least as important as, if not more important
than, changes in CD4 cell count, in evaluating the effectiveness of
antiretroviral therapy. Thus, in evaluating the results of the study,
both measures were considered to be primary from a clinical per-
spective. No post hoc adjustment for multiple end points was made.
The protocol also specified that the 2 pairwise comparisons of the
indinavir-zidovudine-lamivudine and the indinavir monotherapy
groups with the zidovudine-lamivudine group were of primary in-
terest. Per the protocol, multiplicity adjusted P values were cal-
culated to ensure that the overall type I error for these comparisons
was !.050. However, since the multiplicity adjusted P values were
very similar to the nominal P values and since the monotherapy
comparison is no longer of equal importance, only the nominal P
values are reported here. All P values are 2-sided.
Analyses of the proportions of patients who had serum HIV
RNA levels !500 copies/mL at each time point were performed on
an intention-to-treat basis. Two approaches were used to handle
missing data. First, a model-based analysis was done by use of the
generalized estimating equation (GEE) methodology for longitu-
dinal data [7]. Patients who discontinued therapy because of clinical
or laboratory adverse experiences or because of clinical events were
considered to have HIV RNA levels >500 copies/mL (i.e., failure)
after discontinuation of therapy, regardless of RNA level. Missing
values, due to a missed or mistimed visit, were assumed to be !500
copies/mL, if both the immediately preceding and succeeding HIV
RNA levels were !500 copies/mL. A corresponding rule was ap-
plied if both values were >500 copies/mL. Other missing values,
including those subsequent to discontinuation for reasons not
known to be therapy related, were left as missing. The GEE meth-
odology was then used to estimate the proportions of patients with
serum HIV RNA levels !500 copies/mL by treatment group. Con-
ceptually, GEE estimates the proportion from the available (ob-
served and assigned) data at a time point and then adjusts this
estimate based on correlations between the responses at that time
point and all other points and the available data for the patients
who are missing data at that time point. An autoregressive one
(AR [1]) covariance structure was used so that the adjustment was
influenced most by the responses closest to the time point for which
response was being estimated.
A second intention-to-treat analysis was done, in which all pa-
tients who withdrew were counted as treatment failures after they
discontinued therapy (referred to as withdrawal-equals-failure
analysis hereafter). Missing values, due to a missed or mistimed
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Table 1. Patient characteristics at baseline by treatment group.
Characteristics a
Indinavir-zidovudine-lamivudine
(n 5 108)
Indinavir
(n 5 107)
Zidovudine-lamivudine
(n 5 105)
Total
(n 5 320)
Sex, no. (%)
Women 15 (14) 12 (11) 12 (11) 39 (12)
Men 93 (86) 95 (89) 93 (89) 281 (88)
Racial origin, no. (%)
White 81 (75) 90 (84) 87 (83) 258 (81)
Black 17 (16) 9 (8) 13 (12) 39 (12)
Hispanic 8 (7) 4 (4) 3 (3) 15 (5)
Otherb 2 (2) 4 (4) 2 (2) 8 (3)
Age (years), mean (SD) 40.0 (7.9) 37.9 (8.5) 39.5 (8.4) 39.1 (8.3)
Prior zidovudine therapy (months), mean (SD) 27.5 (19.5) 27.5 (22.3) 28.5 (20.9) 27.8 (20.9)
Prior therapy with nucleoside analogs,c no. (%) 92 (85) 87 (81) 93 (89) 272 (85)
Prior AIDS-defining illness, no. (%) 62 (58) 66 (62) 57 (54) 185 (58)
CD4 cells/mm3d
Mean (SD) 19.1 (15.0) 18.3 (12.5) 17.8 (13.5) 18.4 (13.6)
Median 15.0 17.0 14.0 15.0
Range 5.0–63.0 5.0–66.0 5.0–57.0 5.0–66.0
Serum HIV RNA, no. 107 106 98 311
Log10 copies/mL
Mean (SD) 4.83 (0.51) 4.93 (0.55) 4.85 (0.46) 4.87 (0.51)
Median 4.89 4.97 4.98 4.96
Range 3.04–6.08 3.29–6.25 3.60–5.77 3.04–6.25
Copies/mL
Geometric mean 68,151 85,010 70,742 74,353
Median 76,900 94,030 94,430 90,790
Range 1090–1,204,720 1900–1,775,030 4020–590,280 1090–1,775,030
a SD, standard deviation; HIV, human immunodeficiency virus.
b Includes Asian, Asian/White, Asian Indian, South American, Nicaraguan, and other.
c Didanosine, zalcitabine, and stavudine.
d Values reported as !10 cells/mm3 were coded as 5 cells/mm3.
visit, were left as missing, if both the immediately preceding and
succeeding HIV RNA levels were !500 copies/mL; otherwise they
were assumed to be >500 copies/mL. The proportion of subjects
with HIV RNA !500 copies/mL at each time point was estimated
by dividing the number of patients with HIV RNA !500 copies/
mL by the number of patients with available (observed and as-
signed) data. The observed proportions of patients with HIV RNA
!500 copies/mL, based on all observed data regardless of whether
the patients were on study therapy at the time of the measurements,
were also calculated. For all 3 analyses, 95% CIs were calculated.
The same approaches to analysis were used for the proportion
of patients with !50 HIV RNA copies/mL with one exception. Since
data from the more sensitive assay were available at only one time
point during the double-blind portion of the study, the model-based
analysis could not be done for the week-24 data. In these analyses,
it was assumed that samples with >500 copies/mL by the standard
assay had >50 copies/mL by the more sensitive assay.
An intention-to-treat analysis of the changes in CD4 cells at week
84 was done by carrying forward the last observation for subjects
who discontinued therapy because of either clinical or laboratory
adverse experiences or clinical events. Changes from baseline were
then estimated by use of a generalization of analysis of covariance
that allows for correlation and nonconstant variability in longi-
tudinal data. An AR (1) covariance structure was used, and the
model was fitted to the data by use of the method of restricted
maximum likelihood. Baseline CD4 cell count, investigative site,
treatment, week, and treatment by week interaction were included
in the model.
The distribution of the time to the first clinical event was com-
pared pairwise between the treatment groups by use of the log-
rank test stratified by investigative site. An estimate of the relative
risk of disease progression was obtained from the Cox proportional
hazards model with treatment and site as covariates.
Fisher’s exact test was used to compare treatment groups with
respect to the proportions of patients who discontinued the study,
who had adverse experiences, and who had clinically significant
laboratory abnormalities. A clinically significant laboratory ab-
normality was considered present if a value exceeded the predefined
criteria or an abnormality present at baseline became worse.
The planned sample size for this study was 150 patients per
group. With this sample size and assuming an SD of 75 cells/mm3,
there would have been 80% power to detect a difference of 27 cells/
mm3 in the average change from baseline over 24 weeks in CD4
cell counts between indinavir alone or in combination with zido-
vudine plus lamivudine and zidovudine plus lamivudine by use of
a 2-tailed test at the 2.5% significance level.
Results
Patient characteristics. In total, 320 HIV-1–infected sub-
jects were enrolled in the study. The baseline patient charac-
teristics are presented in table 1. The 3 treatment groups were
comparable at baseline. Most subjects were men (88%) and
white (81%). Mean age was 39 years. The mean CD4 cell count
for all patients was 18 cells/mm3. The mean serum HIV-1 RNA
level was 4.87 log10 copies/mL. Nine patients did not have base-
line viral RNA measurements, 1 each in the indinavir and
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Figure 1. Mean changes from baseline in serum human immuno-
deficiency virus (HIV) RNA levels based on observed data for patients
with <50 CD4 cells/mm3 at baseline. Bars are 95% confidence intervals.
indinavir-zidovudine-lamivudine groups and 7 in the zidovu-
dine-lamivudine group.
All patients were zidovudine-experienced, with a mean ex-
posure of 27.8 months, and 85% had previously received at
least one other nucleoside analogue: didanosine, 57%; zalci-
tabine, 51%; or stavudine, 35%. In addition, 5% received nev-
irapine and 1% delavirdine.
More than half the patients (58%) had at least one previous
AIDS-defining illness. The most common illness, experienced
by 28% of the patients, was Pneumocystis carinii pneumonia.
Patient follow-up. Overall, 69 (22%) patients discontinued
their participation in the study prior to completing 24 weeks:
15 (14%) in the indinavir-zidovudine-lamivudine group, 20
(19%) in the indinavir group, and 34 (32%) in the zidovudine-
lamivudine group. The proportion of patients who discontinued
study treatment was significantly lower in the indinavir-
zidovudine-lamivudine and the indinavir groups than in the
zidovudine-lamivudine group ( and .027, respectively).P 5 .002
The difference between the indinavir-zidovudine-lamivudine
group and the indinavir group in the proportion of patients
who discontinued was not significant ( ). Only 20 (6%)P 5 .361
patients discontinued because of a clinical or laboratory adverse
event: 6 in the indinavir-zidovudine-lamivudine group, 5 in the
indinavir group, and 9 in the zidovudine-lamivudine group.
Other reasons for discontinuation were clinical event (3 pa-
tients), patient withdrawal (37), lost to follow-up (5), other (3),
and protocol deviation (1).
Changes in viral RNA. Figure 1 displays the observed mean
changes in HIV RNA from baseline through week 24. Patients
in the indinavir-zidovudine-lamivudine group had the greatest
mean decrease from baseline through week 24. At week 24, the
mean decreases were 1.93, 0.36, and 0.25 log10 copies/mL for
the indinavir-zidovudine-lamivudine, indinavir monotherapy,
and zidovudine-lamivudine groups, respectively. The adjusted
mean decrease (5SE) over the 24-week period (as measured
by AUCMB) was 1.52 (50.07), 0.52 (50.07), and 0.37 (50.07)
log10 copies/mL in the indinavir-zidovudine-lamivudine, indi-
navir, and zidovudine-lamivudine groups, respectively. The de-
crease in the indinavir-zidovudine-lamivudine group was sig-
nificantly greater ( ) than in the indinavir andP ! .001
zidovudine-lamivudine groups. The average decreases over 24
weeks were similar for the indinavir and zidovudine-lamivudine
groups ( ).P 5 .132
Figure 2A displays the proportion of patients with serum
HIV-1 RNA levels !500 copies/mL, as estimated by the model-
based analysis (see Methods). The estimated proportions of
patients with HIV RNA levels !500 copies/mL at week 24 were
60%, 3%, and 0% for the indinavir-zidovudine-lamivudine, in-
dinavir monotherapy, and zidovudine-lamivudine groups, re-
spectively. In the withdrawal-equals-failure analysis, the pro-
portions of patients with HIV RNA levels !500 copies/mL at
week 24 were 56% (60/108), 3% (3/107), and 0% (0/105), re-
spectively. For comparison, based only on observed data, the
proportions of patients with HIV RNA levels !500 copies/mL
were 66% (60/91), 4% (3/85), and 0% (0/68), respectively, at
week 24. Figure 2B displays the results of the 3 methods of
analysis for the indinavir-zidovudine-lamivudine group.
A more sensitive investigational assay was also used to mea-
sure HIV RNA at week 24. In the withdrawal-equals-failure
analysis, the proportions of patients with serum viral RNA
values !50 copies/mL were 45% (48/106) in the indinavir-
zidovudine-lamivudine group, 2% (2/107) in the indinavir
group, and 0% (0/105) in the zidovudine-lamivudine group. The
corresponding observed proportions were 54% (48/89) in the
indinavir-zidovudine-lamivudine group, 2% (2/85) in the indi-
navir group, and 0% (0/68) in the zidovudine-lamivudine group.
HIV RNA measurements were available at week 84 for 64
patients randomized to receive indinavir-zidovudine-lamivu-
dine. Table 2 shows the proportions of patients with serum
HIV RNA levels !500 copies/mL and !50 copies/mL by the 3
methods of analysis.
Changes in CD4 cells. Figure 3 displays the observed mean
changes from baseline in CD4 cells by treatment group. At week
24, patients experienced mean increases of 95, 78, and 6 cells/
mm3 in the indinavir-zidovudine-lamivudine, indinavir, and
zidovudine-lamivudine groups, respectively. The adjusted mean
increases (5SE) in CD4 cells through week 24 (as measured
by the AUCMB) for the respective groups were ,61.3 5 4.5
, and cells/mm3. The increases in the59.9 5 4.6 6.8 5 4.6
indinavir-zidovudine-lamivudine and indinavir groups were sig-
nificantly greater ( ) than in the zidovudine-lamivudineP ! .001
group. The difference between the indinavir-zidovudine-lami-
vudine and indinavir groups was not significant ( ). InP 5 .812
an analysis of data available for 67 patients through week 84,
the observed mean increase in CD4 cells was cells/201 5 14.4
mm3 for subjects randomized to receive indinavir-zidovudine-
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Table 2. Week 84 serum human immunodeficiency virus (HIV) RNA
levels for patients initially randomized to indinavir-zidovudine-
lamivudine.
Analysis
!500 copies/mL !50 copies/mL
n/N (%) 95% CI n/N (%) 95% CI
Observed data 48/64 (75%) (62%–85%) 37/63 (59%) (46%–71%)
Model based — (52%) (42%–62%) — (41%) (32%–51%)
Withdrawal 5 failure 48/107 (45%) (35%–55%) 37/106 (35%) (26%–45%)
NOTE. One patient with HIV RNA !500 copies/mL did not have more
sensitive assay done and is not included in !50 copies/mL analysis. n, no. of
patients with HIV RNA !500 (50) copies/mL; N, no. of patients with measure-
ments for observed data analysis; also includes patients whowithdrawal 5 failure
withdrew. CI, confidence interval.
Figure 2. Proportion of patients with serum human immunodeficiency virus (HIV) RNA !500 copies/mL. A, Model-based estimates for 3
treatment groups. B, Results based on observed data, model-based analysis, and withdrawal-equals-failure analysis for subjects in indinavir-
zidovudine-lamivudine group. Bars are 95% confidence intervals.
lamivudine. In an intention-to-treat analysis, the estimated
mean change was cells/mm3.159 5 8.3
Progression to clinical events. Thirty-six patients (11%) ex-
perienced >1 confirmed clinical event: 11 in the indinavir-zi-
dovudine-lamivudine group, 10 in the indinavir group, and 15
in the zidovudine-lamivudine group. Two patients in the indi-
navir group and 3 in the zidovudine-lamivudine group had a
second confirmed event at a later date. The most common
primary events were Pneumocystis carinii pneumonia (9 pa-
tients) and cytomegalovirus retinitis (5 patients). There were no
significant differences between the treatment groups in the time
to progression to an AIDS-defining illness or death. The esti-
mated hazard ratio comparing indinavir-zidovudine-lamivu-
dine with zidovudine-lamivudine was 0.70 (95% CI, 0.32–1.53);
for comparison of indinavir with zidovudine-lamivudine, it was
0.62 (95% CI, 0.28–1.40).
Five of the 11 patients in the indinavir-zidovudine-lamivu-
dine group who experienced a clinical event did so during the
first 2 weeks of the study. During the first 8 weeks, 7 patients
in each of the indinavir-zidovudine-lamivudine and zidovudine-
lamivudine groups and 4 patients in the indinavir group had
clinical events.
Mortality. Four patients died during the study: none in the
indinavir-zidovudine-lamivudine group, 3 in the indinavir
monotherapy group, and 1 in the zidovudine-lamivudine group.
Of the 4 patients who died, 2 died 4–8 weeks after discontin-
uation of the study drug.
Safety. For each treatment group, the overall occurrence
of adverse events and discontinuations due to adverse events
were similar. The only clinical adverse event that occurred sig-
nificantly more frequently in both indinavir groups than in the
zidovudine-lamivudine group was upper respiratory infection.
Ten (9.3%) patients in the indinavir monotherapy group and 4
(3.7%) in the indinavir-zidovudine-lamivudine group had ad-
verse experiences associated with nephrolithiasis, compared
with 3 (2.9%) in the zidovudine-lamivudine group. Only 1 pa-
tient (in the indinavir group) discontinued the study because
of nephrolithiasis. The differences in the incidence of nephrol-
ithiasis between the treatment groups were not significant.
Table 3 shows the proportion of patients in each treatment
group with laboratory abnormalities for which there were sig-
nificant differences. Total bilirubin levels of >2.5 mg/dL and
elevated triglycerides 1750 mg/dL were more common in the
indinavir treatment groups than in the zidovudine-lamivudine
group. Decreased hemoglobin (!10 g/L) and neutrophil levels
(!1000 and !500 cells/mL) were more common in the zidovu-
dine-lamivudine group than in the indinavir treatment groups.
Discussion
This study is one of the first to focus on the use of triple
therapy in patients with advanced HIV infection, as evidenced
by <50 CD4 cells/mm3 (mean, 18) and extensive prior antire-
troviral therapy. Even in this difficult-to-treat patient popula-
tion, indinavir-zidovudine-lamivudine resulted in the suppres-
sion of serum HIV-1 RNA levels to !500 copies/mL in the
majority of patients over a 24-week period.
The suppression of HIV-1 RNA levels for the indinavir-
zidovudine-lamivudine group was both substantial and durable.
More than 50% of patients had serum HIV-1 RNA levels de-
cline to !500 copies/mL by week 8. In an analysis using ob-
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Figure 3. Mean changes from baseline in CD4 cell count based on
observed data for patients with <50 CD4 cells/mm3 at baseline. Bars
are 95% confidence intervals.
Table 3. Laboratory abnormalities.
Laboratory abnormality
Indinavir-zidovudine-lamivudine
(n 5 108)
Indinavir
(n 5 107)
Zidovudine-lamivudine
(n 5 105)
Hemoglobin !10 g/L 14/108 (13.0) 12/106 (11.3) 29/105 (27.6)a,b
Neutrophils !1000 cells/mL 25/107 (23.4) 12/106 (11.3)c 60/105 (57.1)a,b
Neutrophils !500 cells/mL 4/107 (3.7) 0/106 (0.0) 19/105 (18.1)a,b
Total serum bilirubin >2.5 mg/dL 20/108 (18.5) 8/106 (7.5)c 0/105 (0.0)a,b
Triglycerides 1750 mg/dL 7/108 (6.5) 13/106 (12.3) 0/105 (0.0)b,c
NOTE. N, total no. of patients in treatment group. Data are no. of patients with abnormality/no. of patients with laboratory test (%).
a Significantly different from indinavir-zidovudine-lamivudine ( ) by Fisher’s exact test.P < .01
b Significantly different from indinavir ( ) by Fisher’s exact test.P < .01
c Significantly different from indinavir-zidovudine-lamivudine ( ) by Fisher’s exact test.P < .05
served data at week 24, 66% of the patients with HIV-1 RNA
measurements had levels !500 copies/mL and 54% had levels
!50 copies/mL. In a model-based intention-to-treat analysis,
the estimated proportion of patients with HIV-1 RNA levels
!500 copies/mL after 24 weeks was 60%. Extended follow-up
of this cohort through week 60 and at week 84 suggests that
this degree of HIV RNA suppression has been maintained [8].
An early decrease in serum HIV-1 RNA was also observed
in the indinavir and zidovudine-lamivudine groups but was not
sustained. The average change from baseline for serum viral
RNA was significantly greater for the indinavir-zidovudine-
lamivudine group, compared with the other 2 groups. The av-
erage change from baseline for the indinavir group, however,
was not significantly different from that for the zidovudine-
lamivudine group.
Elevations in CD4 cell counts were demonstrated in both
indinavir treatment groups. These elevations persisted through-
out the study period. The maximum effect in the zidovudine-
lamivudine group was seen early and was both minimal and
transient. The average change from baseline in CD4 cells was
significantly greater for each of the indinavir treatment groups,
compared with the zidovudine-lamivudine group. However,
there was not a significant difference between the indinavir-
zidovudine-lamivudine group and the indinavir group with re-
gard to CD4 cell changes.
These results demonstrate that persons with advanced AIDS
can have substantial responses to indinavir-zidovudine-lami-
vudine therapy. Patients receiving this 3-drug combination re-
ceived 2 potent antiretroviral agents that had not been used
previously in their treatment regimen.
Patients receiving indinavir alone had an early 1 log decline
in serum HIV-1 RNA, which began to diminish by week 8.
Despite this unsustained serum HIV-1 RNA response, persist-
ent increases in CD4 cells were observed. The reasons for the
discordance between sustained CD4 cell increases and transient
serum HIV-1 RNA responses in the indinavir monotherapy
group are unclear, but similar discordances have also been ob-
served by others [9]. These results confirm the observation that
persons receiving an indinavir treatment regimen maintain sub-
stantial increases in CD4 cells even after loss of initial viral
RNA response.
Clinical progression, defined as the first occurrence of an
AIDS-defining illness or death, occurred in 11% of patients
during the 24 weeks of the study. The differences among the
treatment groups in time to progression were not significant,
but the study was not powered to detect differences in clinical
efficacy. Thus, this study cannot directly demonstrate that the
antiretroviral effect provides clinical benefit, although this was
shown in a large clinical end-point study using the same regimen
[1].
The adverse events observed in this study were similar to
those observed in other indinavir studies, with the exception of
elevated triglycerides [1, 2, 10–12]. In this study, elevated tri-
glycerides were observed more often in the indinavir groups. It
is possible that persons with advanced HIV infection who are
on multiple concomitant medications are more susceptible to
this complication. Zidovudine-associated hematologic toxicity
(anemia, neutropenia) was diminished in the 3-drug group, per-
haps because of better control of underlying HIV infection.
Twenty-two percent of subjects discontinued the study prior
to completing 24 weeks. The study began enrolling patients in
August 1995 prior to approval and widespread availability of
indinavir and lamivudine. As these drugs became available, the
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proportion of patients who discontinued the study increased.
In addition, although patients and investigators did not have
access to the HIV-1 RNA results, which were considered ex-
perimental at the start of the study, they did have access to all
other laboratory results, including CD4 cell counts.
The overall results should not be affected by the dropout
rate, since significantly more subjects dropped from the zido-
vudine-lamivudine group, the arm that showed the least effi-
cacy, than from the indinavir groups. However, dropouts from
the study result in missing data that can make study results
difficult to interpret. This is particularly apparent in presenting
the proportion of patients with HIV RNA of !500 copies/mL,
where missing data may disproportionately decrease the de-
nominator leading to an artifactually high proportion. In order
to address these issues, we used a model-based approach using
GEE methodology for longitudinal data to estimate this pro-
portion [7]. Patients who discontinued study participation be-
cause of adverse experiences or clinical events were counted as
failures at subsequent time points. The proportion of patients
with suppression of RNA was estimated from the available data
and then adjusted based on the correlations between these data
and the available data for patients who discontinued for other
reasons or who missed a scheduled visit. This allows for an
intention-to-treat analysis, since data for all randomized pa-
tients are used. In this study, the model-based approach resulted
in an estimated proportion of 60% of patients receiving triple
combination therapy having HIV RNA !500 copies/mL at
week 24, whereas the observed proportion was 66%. The issue
of dealing with missing data is important in presenting data
from clinical trials, and this model-based approach may provide
an alternative approach for presenting such information.
This study extends the favorable results of combination ther-
apy with indinavir-zidovudine-lamivudine to persons with ad-
vanced AIDS and shows that such persons can tolerate and
benefit from this 3-drug combination therapy. The results also
support the concept of earlier versus later therapy, since the
overall benefits, with respect to numbers of patients obtaining
and maintaining undetectable HIV RNA levels, were muted
when compared with a similar trial in patients with earlier dis-
ease [2, 3]. In treating HIV-infected persons, the best results are
obtained when several potent new drugs are started together
relatively early in the course of infection. These data, along
with other recent studies, show that, with potent combination
therapy, many HIV-infected persons can expect to achieve long-
term suppression of serum viral RNA. The challenge we now
face is maintaining viral suppression with regimens that are
generally well tolerated and easy to use.
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